Cipla Primes For US Momentum But Seretide Generic Is Slow In UK
Cipla reported a strong second quarter, with management upbeat about building momentum in the US business with a “good mix” of differentiated launches. The ramp-up of the firm’s Seretide generic in the UK, though, appears slow.
You may also be interested in...
Cipla's US business appears set to gain momentum with a string of differentiated generic launches lined up and the firm's CEO shares key insights into how price peaks and troughs could potentially play out in the world's largest pharmaceutical market.
The Australian respiratory market seems set for a potential spurt in activity. Cipla and Sandoz appear to be gearing to take their respective competing versions of GlaxoSmithKline’s Seretide to Australia, piling up pressure on the UK multinational’s therapy there.
Cipla's generic version of Seretide has finally received regulatory approval in the UK, bringing much needed relief to investors and opening up more competition for GlaxoSmithKline on its home turf.